10-QPeriod: Q1 FY1995

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 1995

Filed May 12, 1995For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb Co. filed its 10-Q for the period ending March 30, 1995. While specific financial performance details are not present in the provided excerpt, this filing marks a routine update for investors regarding the company's financial standing and operational developments in the first quarter of 1995. Investors should look for information on revenue, profitability, and any significant events or strategic shifts that may impact future performance. As a major pharmaceutical company, BMY's performance is closely tied to its product pipeline, sales of existing drugs, and regulatory approvals. This report would typically provide insights into the company's ability to maintain its competitive edge and drive growth in a dynamic healthcare market. Investors are advised to review the full filing for a comprehensive understanding of the company's financial health and outlook.

Key Highlights

  • 1This is a 10-Q filing for Bristol Myers Squibb Co. for the period ending March 30, 1995.
  • 2The filing was made on May 11, 1995.
  • 3The provided text is a directory listing from the SEC EDGAR database and does not contain specific financial figures or narrative management discussion from the 10-Q report.
  • 4Key information such as revenue, net income, cash flow, and balance sheet details are typically found within the full 10-Q document.
  • 5Investors would need to access the full .txt or HTML version of the filing to analyze the company's financial performance and operational highlights for the quarter.
  • 6The filing indicates routine reporting to the SEC, essential for investor transparency.

Frequently Asked Questions

This 10-Q filing is a quarterly report submitted by Bristol Myers Squibb Co. to the Securities and Exchange Commission (SEC). Its purpose is to provide investors and the public with an update on the company's financial performance and position during the first quarter of 1995.

The provided text is a directory listing from the SEC's EDGAR database and does not contain the actual financial statements or management's discussion and analysis. To find the specific financial results, you would need to access the full 10-Q filing, likely available as a .txt or HTML document within the SEC's EDGAR system, by searching for the company and the filing date.

Investors typically look for key financial metrics such as revenue growth from core products, profitability trends, updates on research and development pipeline progress, any significant product approvals or setbacks, details on debt levels, and management's outlook for the upcoming quarters. For BMY, specific attention is often given to their key therapeutic areas and competitive landscape.